In cases of peripheral applications, such brain‐specific promoters are especially important, as the absence of FMRP outside the CNS may help prevent an immune reaction against the FMR1 transgene product in FXS individuals who have not encountered FMRP in their previous life. The gene discussed is FMR1; the disease is fragile X syndrome.